Efficient Screening for Pharmaceutical Amelioration of FXS Behavioral Deficits in Drosophila

With a $112,250 grant from FRAXA Research Foundation over 3 years, Dr. Efthimios Skoulakis and his team from the Institute of Cellular and Developmental Biology conducted the first FRAXA project in Greece, where they developed a speedy new test for learning problems in fruit flies, which allowed them to test a number of drugs that are potential Fragile X treatments.

Results published: Learning and Memory Deficits Consequent to Reduction of the Fragile X Mental Retardation Protein Result from Metabotropic Glutamate Receptor-Mediated Inhibition of cAMP Signaling in Drosophila
$112,250 Grant
Efthimios Skoulakis, PhD
Principal Investigator
Institute of Cellular and Developmental Biology
2009-11 FRAXA Research Grant
$112,250 over 3 Years

Patients with Fragile X syndrome (FXS) present a range of developmental and behavioural deficits with mild to severe mental retardation, attention deficit disorder, autistic behaviours and problems related to anxiety such as hyperactivity among others. FXS results from loss of FMR1 gene expression often by CGG triplet expansion in the 5’ untranslated region of the gene. Recently even in carriers of CGG expansion permutation in the fmr1 gene were found to suffer age dependent ataxia, short term memory difficulties, anxiety and irritability (FXTAS). Based on the multiple molecules that interact with the FMR Protein (FMRP) in the various neurons of the nervous system, we suggested that the broad range of behavioral deficits associated with FXS reflect impairment of distinct processes in neuronal circuits mediating these particular behaviours and may then requires specific pharmaceutical treatment to ameliorate them.

In the laboratory we worked with a Drosophila model of FXS where affected fruitflies display learning and memory difficulties, attention deficits and hyperactivity. We had been using this model to test pharmaceuticals like the mGlu receptor inhibitors MPEP and Fenobam for amelioration of these behavioural difficulties. In accord with our hypothesis, we found that particular pharmaceuticals are best at ameliorating particular symptoms and so good towards control of others. This suggested to us that pharmaceutical “cocktails” are the most likely approach at controlling all symptoms, or the majority exhibited by a particular patient.

Therefore, with FRAXA support, we developed a fast and efficient method to screen through pharmaceuticals that control hyperactivity, a symptom not ameliorated by mGlu receptor inhibitors. Affected flies fed pharmaceuticals were automatically monitored for their locomotor activity which in untreated individuals is at least twice as much as that of controls.

Our continued screen had identified a couple of previously unexpected compounds to affect the hyperactivity of the FXS flies and in a next step we tested mixtures of these with mGlu receptor inhibitors, whether they also ameliorate learning, memory and attention difficulties. The screen continued until all major classes of pharmaceuticals that target molecules known to serve learning, memory, attention and anxiety/hyperactivity had been tested. We also hoped to test their efficacy on a model of FXTAS in the near future.

Alexandros Kanellopoulos, PhD
Graduate Student

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.

Share via
Copy link